pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » Tranzyme, Inc. (TZYM): The Odds Are Good at Dollar Level

Tranzyme, Inc. (TZYM): The Odds Are Good at Dollar Level

Posted on November 15, 2012 by PennyStockHaven in Commentary, Stock Market News - No Comments
TZYM logo

Tranzyme, Inc. (TZYM) announced today that its drug candidate, TZP-102, did not meet its primary efficacy endpoint. Tranzyme’s Phase IIb study was for two doses of TZP-102 taken once daily against a placebo. Even all patients saw a reduction in gastroparesis symptoms after 12 weeks of treatment, the difference between TZP-102 and placebo was minimum and not statistically significant.

Vipin K. Garg, PhD, President and Chief Executive Officer of Tranzyme, commented:

We are understandably disappointed with the results of this trial; however, our second Phase 2b trial known as DIGEST is ongoing. In DIGEST we are evaluating a 10 mg dose of TZP-102 administered three times daily before meals, rather than once daily as in the trial just completed. We anticipate announcing top line results for DIGEST in the first half of 2013

Gastroparesis is a progressive disorder that causes paralysis of a stomach which leads to nausea, vomiting and digestion problems. There are no currently approved drugs to treat gastroparesis and TZYM’s outgoing Phase 2b DIGEST study may be a solution for the treatment that makes TZYM shares attractive at price below a dollar level.

We believe that TZYM shares will bounce back up in a near-term.

Cash-reach company – market capitalization 50% below TZYM’s cash/share.

DIGEST study is outgoing – preliminary data should be at the beginning of 2013.

 

TZYM logo5001 South Miami Boulevard
Suite 300
Durham, North Carolina 27703
Tel: 919-474-0020
Fax: 919-474-0025

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders.

Tranzyme, TZYM

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • CVR Partners, LP (NYSE: UAN): the dividend play

    February 26, 2023
  • Sotera Health

    Sotera Health Company (NASDAQ:SHC): hard road ahead

    February 21, 2023
  • ZIM Integrated Shipping Services (NYSE:ZIM) uphill movement

    February 20, 2023
  • Carvana Co. (NYSE: CVNA) way to go… down

    February 17, 2023
  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved